Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT162b2 booster doses in previously vaccinated individuals
NCT04955626Phase 3Completed
- Sponsor
- BioNTech SE
- Start
- Jul 2021
- Primary completion
- May 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of tozinameran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by BioNTech SE. Primary endpoints: Occurrence of First COVID-19 Infection After Booster Dose, Adverse Events at 6 months and 8 more. Started Jul 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04955626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04955626.